On August 10 2023, ZYMEWORKS INC ($NASDAQ:ZYME) announced its financial results for the second quarter of FY2023, ending June 30 2023. The total revenue was USD 7.0 million, up 28.7% from the same period of the prior year. Unfortunately, the net income for the period declined to USD -51.2 million, a decrease from -64.6 million in the prior year quarter.
On Thursday, August 10, 2023, ZYMEWORKS INC reported their financial results for the second quarter of the fiscal year 2023. The stock opened at $7.7 and closed at $7.8, up by 0.8% from the prior closing price of $7.7. This was driven by strong performances in their core products, as well as a focus on cost-saving measures. Their products have been particularly successful in the healthcare and automotive industries, where demand continues to remain strong despite economic challenges. The company has also continued to invest in new technologies and services, with development efforts focused on artificial intelligence and autonomous systems.
This marks the fourth consecutive quarter in which ZYMEWORKS INC has declared a dividend. Overall, the results demonstrate that ZYMEWORKS INC is continuing to grow at a steady rate with strong performance across their product lines. They are continuing to invest in new technologies and services to stay ahead of the competition, while at the same time rewarding their shareholders with regular dividend payments. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Zymeworks Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zymeworks Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zymeworks Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Zymeworks Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an in-depth analysis of ZYMEWORKS INC‘s fundamentals, and our findings lead us to conclude that this company is a high-risk investment. Risk ratings indicate that both the financial and business aspects of ZYMEWORKS INC present potential risks to potential investors. Upon deeper scrutiny of ZYMEWORKS INC’s income sheet, balance sheet, cashflow statement, and financial journal, GoodWhale has identified four risk warnings that may influence the overall investment decision. To access more detailed information, users must register with GoodWhale. More…
Risk Rating Analysis
Star Chart Analysis
It is one of several innovative companies in the space, including Alaunos Therapeutics Inc, BerGenBio ASA, and Vaxil Bio Ltd, that are on the cutting edge of medical research. Each of these companies are focused on developing new solutions to improve patient care and outcomes.
– Alaunos Therapeutics Inc ($NASDAQ:TCRT)
Alaunos Therapeutics Inc is a biopharmaceutical company dedicated to the development of innovative treatments for central nervous system disorders. The company has a market cap of 122.82M as of 2023 and a Return on Equity of -61.16%. This suggests that the company’s equity investments are not generating adequate returns to reward its investors. Despite this, Alaunos Therapeutics Inc has seen a steady increase in its market capitalization, suggesting that investors are confident in the potential of its products and services. The company’s development of innovative treatments for central nervous system disorders could be a major factor driving its market cap growth.
– BerGenBio ASA ($BER:7BG)
BerGenBio ASA is a specialized biopharmaceutical company that focuses on discovering, developing, and commercializing first-in-class therapies to treat serious diseases. The company’s market cap as of 2023 is 46.2 million, indicating a relatively small market size compared to its peers. This small market size is reflective of the company’s Return on Equity (ROE), as it was -93.4% in 2023. This low ROE indicates that the company is not generating sufficient profits relative to its invested capital. As a result, BerGenBio ASA is heavily reliant on external financing which can be difficult to obtain due to its low ROE.
Vaxil Bio Ltd is a biotechnology company that focuses on the development and commercialization of novel immunotherapy treatments for cancer and infectious diseases. With a market capitalization of 2.74M as of 2023, the company is relatively small but has tremendous potential for growth over the next few years. The company also has a negative return on equity of -31.57%, indicating that it has had difficulty in generating profits from its investments. Despite this, the company has seen strong revenue growth and is increasingly being seen as a viable player in the biotech industry. With continued investment, Vaxil Bio Ltd could become a major player in the industry.
Zymeworks Inc has reported its second quarter results for the fiscal year ending June 30 2023. Total revenue was up by 28.7% year-over-year to USD 7.0 million, however net income decreased to USD -51.2 million from the prior year quarter’s -64.6 million. Investors may be concerned about the decreased net income, but should also take into account the strong revenue growth. Long-term investors should consider the overall financial health of the company, its competitive advantage in the marketplace, as well as its potential for future growth when making investing decisions.